Zai Lab Ltd Contracts & Agreements
28 Contracts & Agreements
- Business Finance (6 contracts)
- Business Operations (6)
- Human Resources (7)
- Intellectual Property (5)
- Real Estate (1)
- Uncategorized (3)
- Collaboration and License Agreement by and between Seagen Inc. and Zai Lab (Hong Kong) Limited dated as of September 23, 2022 (Filed With SEC on November 9, 2022)
- Form of Restricted Share Unit Award Agreement (Filed With SEC on November 9, 2022)
- Form of Restricted Stock Award Agreement (Filed With SEC on November 9, 2022)
- Form of Non-Statutory Stock Option Award Agreement (Filed With SEC on November 9, 2022)
- Zai Lab Limited 2022 Equity Incentive Plan (Filed With SEC on June 22, 2022)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act (Filed With SEC on May 10, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on March 1, 2022)
- License and Collaboration Agreement by and between Zai Lab (Shanghai) Co., Ltd. and Blueprint Medicines Corporation, dated November 8, 2021 (Filed With SEC on March 1, 2022)
- License Agreement by and between Zai Lab (Shanghai) Co., Ltd. and Karuna Therapeutics, Inc., dated November 8, 2021 (Filed With SEC on March 1, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on November 9, 2021)
- Registrants Specimen Certificate for Ordinary Shares (Filed With SEC on August 9, 2021)
- Amendment to the Amended and Restated Employment Agreement, dated as of May 7, 2021, by and between Zai Lab (US) LLC and Tao Fu (Filed With SEC on August 9, 2021)
- Collaboration and License Agreement, dated as of May 28, 2021, by and between Zai Lab (Hong Kong) Limited and Mirati Therapeutics, Inc (Filed With SEC on August 9, 2021)
- License and Collaboration Agreement, dated as of June 15, 2021, by and between Zai Lab (US) LLC and MacroGenics, Inc (Filed With SEC on August 9, 2021)
- Collaboration and License Agreement between argenx BV and Zai Auto Immune (Hong Kong) Limited dated January 6, 2021 (Filed With SEC on May 10, 2021)
- License Agreement between Turning Point Therapeutics, Inc. and Zai Lab (Shanghai) Co., Ltd. dated January 10, 2021 (Filed With SEC on May 10, 2021)
- Amendment No. 1 to License Agreement between Turning Point Therapeutics, Inc. and Zai Lab (Shanghai) Co., Ltd. dated March 31, 2021 (Filed With SEC on May 10, 2021)
- Form of Underwriting Agreement with respect to ADSs (Filed With SEC on April 21, 2021)
- Form of Underwriting Agreement with respect to Ordinary Shares (Filed With SEC on April 21, 2021)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act (Filed With SEC on March 1, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on March 1, 2021)
- Collaboration Agreement between Regeneron Ireland Designated Activity Company and Zai Lab (Shanghai) Co., Ltd. dated April 6, 2020 (Filed With SEC on March 1, 2021)
- License Agreement between Turning Point Therapeutics, Inc. and Zai Lab (Shanghai) Co., Ltd. dated July 6, 2020 (Filed With SEC on March 1, 2021)
- License Agreement between Cullinan Pearl Corp. and Zai Lab (Shanghai) Co., Ltd. dated December 24, 2020 (Filed With SEC on March 1, 2021)
- Employment Agreement between F. Ty Edmondson and Zai Lab (US) LLC dated August 15, 2020 (Filed With SEC on March 1, 2021)
- Employment Agreement between Alan Bart Sandler and Zai Lab (US) LLC dated December 1, 2020 (Filed With SEC on March 1, 2021)
- Lease by and between Menlo Prepi I, LLC, TPI Investors 9, LLC and Zai Lab (US) LLC dated August 14, 2019 (Filed With SEC on March 1, 2021)
- Indenture of Lease by and between MIT 314 Main Street Leasehold LLC and Zai Lab (US) LLC dated December 22, 2020 (Filed With SEC on March 1, 2021)
